SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 959.16 |
| Enterprise Value ($M) | 1,211.88 |
| Book Value ($M) | 674.96 |
| Book Value / Share | 10.68 |
| Price / Book | 1.42 |
| NCAV ($M) | -224.33 |
| NCAV / Share | -3.55 |
| Price / NCAV | -4.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.16 |
| Return on Assets (ROA) | 0.16 |
| Return on Equity (ROE) | 0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.96 |
| Current Ratio | 9.03 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 344.22 |
| Assets | 1,243.51 |
| Liabilities | 568.55 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 310.46 |
| Operating Income | 113.89 |
| Net Income | 179.72 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 141.06 |
| Cash from Investing | -66.76 |
| Cash from Financing | -171.84 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Tang Capital Partners Lp | 100.00 | -100.00 | |
| 13G/A | Putnam Investments Llc | 9.80 | 17.66 | |
| 13G/A | Renaissance Technologies Llc | 6.47 | -2.01 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 10.47 | -5.09 | |
| 13G | Dimensional Fund Advisors Lp | 7.00 | ||
| 13G/A | BlackRock Inc. | 16.10 | -2.48 | |
| 13D/A | Orbimed Advisors Llc | 40.10 | 0.00 | |
| 13D/A | Foresite Capital Fund V, L.P. | 12.40 | 0.00 | |
| 13G/A | Fmr Llc | 0.00 | -99.95 | |
| 13D/A | Sarissa Capital Management LP | 10.54 | 7.64 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 69,356 | 325,402 | 21.31 | |
| 578,190 | 1,410,985 | 40.98 | |
| 69,940 | 649,492 | 10.77 | |
| 105,599 | 246,424 | 42.85 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INDV – Indivior PLC | INNV – InnovAge Holding Corp. |
| INSM – Insmed Incorporated | INZY – Inozyme Pharma, Inc. |
| IOBT – IO Biotech, Inc. |